Effect of Maintenance Ustekinumab on Corticosteroid-Free Clinical Outcomes in Patients with Crohn’s Disease
Brian G. Feagan(Western University), Subrata Ghosh(University College Cork), Long-Long Gao(Janssen (United States)), Miao Ye(Western University), Paul Pollack(Reckitt Benckiser (United States)), Christopher Gasink(Janssen (United States)), Jewel Johanns(Johnson & Johnson (United States)), Stephan R. Targan(Cedars-Sinai Medical Center)
Cited by 3
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k